<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128618</url>
  </required_header>
  <id_info>
    <org_study_id>CM-2019</org_study_id>
    <nct_id>NCT04128618</nct_id>
  </id_info>
  <brief_title>Evaluation of a Home-based NMES Therapy for Knee Osteoarthritis Pain</brief_title>
  <acronym>NMES</acronym>
  <official_title>A Randomized, Sham Controlled, Double-blind, Multi-center Study of Neuromuscular Electrical Stimulation (NMES) as an Adjunctive Therapy for Knee Pain Relief and Improving Functional Outcomes in Knee Osteoarthritis (OA) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CyMedica Orthopedics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CyMedica Orthopedics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of knee pain and functional mobility of knee osteoarthritis patients with a&#xD;
      home-based neuromuscular electrical stimulation (NMES) therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Actual">November 24, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects, coordinators, and Investigators are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Knee pain using VAS scale (Visual Analog Scale)</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Pain associated with knee osteoarthritis- Unit none (score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed Up &amp; Go (TUG)</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Mobility and functionality assessment of the knee- Timed Up &amp; Go (TUG), unit seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps muscle strength</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Strength assessment, Quadriceps strength using a handheld dynamometer, unit lbs/in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeated Chair Rise</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Mobility and functionality assessment of the knee- Repeated chair rise, unit none (number of times)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 min walk test</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Mobility and functionality assessment of the knee- 3 min walk test, unit meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS JR. Survey</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Mobility and functionality assessment of the knee- KOOR JR- Unit, none (score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Survey</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Mobility and functionality assessment of the knee- WOMAC- Unit, none (score)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Active NMES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified NMES sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CyMedica e-vive NMES</intervention_name>
    <description>Neuromuscular Electrical Stimulation (NMES) therapy</description>
    <arm_group_label>Active NMES</arm_group_label>
    <arm_group_label>Modified NMES sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must provide written, informed consent before any study procedures occur. The&#xD;
             subject should be provided with a copy of the signed Informed Consent upon signature.&#xD;
&#xD;
          2. Subjects with symptomatic Kellgren-Lawrence (KL) Grade 2, 3, or 4 OA by radiograph (AP&#xD;
             tunnel view) within 30 days prior to day 0 visit, where the K-L grades are defined as:&#xD;
&#xD;
               -  Grade 0: no radiographic features of OA are present&#xD;
&#xD;
               -  Grade 1: doubtful joint space narrowing (JSN) and possible osteophytic lipping&#xD;
&#xD;
               -  Grade 2: definite osteophytes and possible JSN on anteroposterior weight-bearing&#xD;
                  radiograph&#xD;
&#xD;
               -  Grade 3: multiple osteophytes, definite JSN, sclerosis, possible bony deformity&#xD;
&#xD;
               -  Grade 4: large osteophytes, marked JSN, severe sclerosis and definite bony&#xD;
                  deformity&#xD;
&#xD;
          3. Subject must have a normal tibiofemoral angle (0-8°) and a joint space width of ≥ 3mm&#xD;
             confirmed by radiograph.&#xD;
&#xD;
          4. Subjects who are between the ages of 21 - 85 years.&#xD;
&#xD;
          5. Subjects must have a visual analog pain (VAS) score of at least 4 cm on a 10 cm scale&#xD;
             for a nominated activity in the target knee at the time of screening.&#xD;
&#xD;
          6. For bilateral knee osteoarthritis subjects, the visual analog pain VAS score for a&#xD;
             nominated activity of the contralateral knee must be less than 4 cm on the VAS scale.&#xD;
&#xD;
          7. Subject has access to a smartphone or tablet (Android or iOS).&#xD;
&#xD;
          8. Subject must be ambulatory.&#xD;
&#xD;
          9. Subject must be willing to discontinue receiving knee intra-articular injections of&#xD;
             steroids, knee intra-articular injections of hyaluronic acid, opioids, and analgesics&#xD;
             (except for acetaminophen up to 3000 mg/day or an equivalent) for the duration of the&#xD;
             study.&#xD;
&#xD;
         10. Subject must be willing to take acetaminophen (up to 3000 mg/day) or an equivalent as&#xD;
             pain medication for the duration of the study.&#xD;
&#xD;
         11. Subject must be willing to stop taking any pain medications 24 hours prior any&#xD;
             scheduled study visit.&#xD;
&#xD;
         12. Subject must be willing to stop receiving knee physical therapy of the target knee for&#xD;
             the duration of the study.&#xD;
&#xD;
         13. Subject must be willing to stop wearing any knee unloader brace of the target knee for&#xD;
             the duration of the study.&#xD;
&#xD;
         14. Subjects must be proficient in English.&#xD;
&#xD;
         15. Subjects must be willing and able to comply with all study procedures for the duration&#xD;
             of the clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have a body mass index ≥ 40 at the time of consent (at the discretion of&#xD;
             the PI).&#xD;
&#xD;
          2. Subjects with a diagnosis of inflammatory arthritis (knee rheumatoid arthritis, active&#xD;
             gout, knee joint infection, Lyme disease, SLE, etc.).&#xD;
&#xD;
          3. Subjects with a diagnosis of severe neuropathy condition for the past 6 months and&#xD;
             under medication for treatment of the condition.&#xD;
&#xD;
          4. Subjects with a diagnosis of fibromyalgia for the past year.&#xD;
&#xD;
          5. Subjects who have had an injury or an acute traumatic injury to the target knee within&#xD;
             6 months of screening.&#xD;
&#xD;
          6. Subject must NOT have had arthroscopy of the target knee within 8 weeks of&#xD;
             randomization.&#xD;
&#xD;
          7. Subjects who have had treatment of the target knee with intra-articular injections of&#xD;
             steroids within 8 weeks of screening.&#xD;
&#xD;
          8. Subjects who have had intra-articular injections of hyaluronic acid within 12 weeks of&#xD;
             screening.&#xD;
&#xD;
          9. Subjects who have had a scheduled surgery on the target knee within the study period.&#xD;
&#xD;
             (Note- Subjects who are scheduled to go under total knee replacement surgery within&#xD;
             the next 3 months at screening will not be enrolled. Subjects that are contemplating&#xD;
             the surgery can be included.)&#xD;
&#xD;
         10. Subjects who have used electrotherapy or acupuncture for OA of the target knee within&#xD;
             4 weeks of screening.&#xD;
&#xD;
         11. Subjects who have used Neuromuscular Electrical Stimulation (NMES) in the past year.&#xD;
&#xD;
         12. Subjects with significant and clinically evident mal-alignment of the target knee (&gt; 5&#xD;
             degrees varus or valgus in the target knee).&#xD;
&#xD;
         13. Subjects with surgical metallic hardware in the target knee.&#xD;
&#xD;
         14. Subjects who have had implanted electrical devices (cardiac pacemakers, deep brain&#xD;
             stimulators, implantable cardiac defibrillators).&#xD;
&#xD;
         15. Subjects who have contraindications to X-rays.&#xD;
&#xD;
         16. Subjects with a current malignancy or who have received treatment for malignancy with&#xD;
             the last 5 years, with the exception of resected basal cell carcinoma and squamous&#xD;
             cell carcinoma of the skin.&#xD;
&#xD;
         17. Subjects who have an active substance abuse problem (drugs or alcohol) or a history of&#xD;
             chronic substance abuse (&gt; 5 years).&#xD;
&#xD;
         18. Subjects with skin breakdown or infection in the area where the study device will be&#xD;
             placed (quadriceps of the target knee).&#xD;
&#xD;
         19. Subjects with any chronic conditions (e.g., diabetes, hypertension, congestive heart&#xD;
             failure, etc.) that have not been well-controlled for at least 3 months prior to&#xD;
             screening.&#xD;
&#xD;
         20. Subjects who have any ongoing litigation for worker's compensation.&#xD;
&#xD;
         21. Subjects with any condition, in the opinion of the Investigator that might interfere&#xD;
             with the evaluation of the study objectives.&#xD;
&#xD;
         22. Subjects who are pregnant.&#xD;
&#xD;
         23. Subject must not have participated in a clinical study within the past 12 weeks from&#xD;
             the last day of treatment that required the use of an investigational device, drug or&#xD;
             biologic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Noble Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>knee OA</keyword>
  <keyword>arthritis</keyword>
  <keyword>knee pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

